Treatment of the sibilancias appellants/asthmas in the child younger than 3 years of age;Tratamiento de las sibilancias recurrentes/asma en el niño menor de 3 años de edad

Pediatria de Atencion Primaria

Volumn 11, Issue 41, 2009, Pages 97-120

  Ubeda Sansano M I ^a   Murcia Garcia J ^b   Castillo Laita, J A ^c  

^a Departamento 6   (Spain)

^b CS San Felipe   (Spain)

^c Centro de Salud Fuentes de Ebro   (Spain)

Author keywords

Asthma; Children; Infant; Preschool; Recurrent wheezing; Treatment

Indexed keywords

EID: 75649141813     PISSN: 11397632     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Warner JO, Naspitz CK. Third International Pediatric Consensus statement on the management of childhood asthma. International Pediatric Asthma Consensus Group. Pediatr Pulmonol. 1998;25:1-17.
2. Castillo JA, de Benito J, Escribano A y col. Consenso sobre tratamiento del asma en pedia-tría. An Pediatr (Barc). 2007;67:253-73.
3. Bacharier LB, Boner A, Carlsen KH. Diagno-sis and treatment of asthma in childhood: a PRACTALL consensus report. Allergy. 2008;63: 5-34.
4. Praena Crespo M. ¿A qué llamamos asma infantil? Rev Pediatr Aten Primaria. 2005;7 (2 Sup):S13-27.
5. Brand PLP, Baraldi E, Bisgaard H. Definition, assessment and treatment of wheezing disorders in preschool children: an evidence-based appro-ach. Eur Respir J. 2008;32:1096-110.
6. Phelan PD, Robertson CF, Olinsky A. The Melbourne Asthma Study: 1964-1999. J Allergy Clin Immunol. 2002;109:189-94.
7. Taussig LM, Wright AL, Holberg CJ, Halo-nen M, Morgan WJ, Martínez FD. Tucson Chil-dren's Respiratory Study: 1980 to present. J Allergy Clin Immunol. 2003;111:661-75.
8. Martinez FD, Godfrey S. Management of wheezing in infants and preschool children. En: Martinez FD, Godfrey S, edit. Wheezing disorders in the preschool child. New York: Martin Dunitz; 2003. p. 123-42.
9. Boehmer AL, Merkus PJ. Asthma therapy for children under 5 years of age. Curr Opin Pulm Med. 2006;12:34-41.
10. Saglani S, Malmström K, Pelkonen AS. Air-way remodeling and inflammation in symptoma-tic infants with reversible airflow obstruction. Am J Respir Crit Care Med. 2005;171:722-7.
11. Saglani S, Payne DN, Zhu J. Early detec-tion of airway wall remodeling and eosinophilic inflammation in preschool wheezers. Am J Respir Crit Care Med. 2007;176:858-64.
12. Castro-Rodríguez JA, Holberg CJ, Wright AL, Martinez FD. A clinical index to define risk of asthma in young children with recurrent whee-zing. Am J Respir Crit Care Med. 2000;162: 1403-6.
13. Guilbert TW, Morgan WJ, Zeiger RS. Ato-pic characteristics of children with recurrent wheezing at high risk for the development of childhood asthma. J Allergy Clin Immunol. 2004;14:1282-7.
14. Korta J, Valverde J, Praena M. La educa-ción terapéutica en el asma. An Pediatr (Barc). 2007;66:496-517.
15. Gdalevich M, Mimouni D, Mimouni M. Breast-feeding and the risk of bronchial asthma in childhood: a systematic review with meta-analysis of prospective studies. J Pediatr. 2001; 139:261-6.
16. Zutavern A, Brockow I, Schaaf B, von Berg A, Diez U, Borte M, et al. Timing of solid intro-duction in relation to eczema, asthma, allergic rhinitis, and food and inhalants sensitization at the age of 6 years: results from the prospective birth cohort study LISA. Pediatrics. 2008;121: e44-52.
17. Cates CJ, Jefferson TO, Rowe BH. Vaccines for preventing influenza in people with asthma. Cochrane Database of Systematic Reviews 2008, Issue 2. Art. No.: CD000364.
18. Lannerö E, Wickman M, Pershagen, Nord-vall L. Maternal smoking during pregnancy in-creases the risk of recurrent wheezing during the first years of life (BAMSE). Respir Res. 2006;7:3.
19. Buñuel Álvarez JC, Montón Álvarez JL. Los hijos de madres que fumaron durante la gesta-ción presentaron una mayor incidencia de enfer-medades respiratorias de vías bajas durante los dos primeros años de vida. Evid Pediatr. 2006;2: 30 [consultado el 13/01/2009]. Disponible en www.aepap.org/EvidPediatr/index.htm
20. Hofhuis W, de Jongste JC, Merkus PJ. Ad-verse health effects of prenatal and postnatal to-bacco smoke exposure on children. Arch Dis Child. 2003;88:1086-90.
21. Piippo-Savolainen E, Korppi M. Wheezy babies-wheezy adults? Review on long-term outcome until adulthood after early childhood wheezing. Acta Paediatr. 2008;97:5-11.
22. Úbeda Sansano MI. Tratamiento de la cri-sis asmática en atención primaria. Acta Pediatr Esp. 2004;62:153-62.
23. Smith SR, Baty JD, Hodge D III. Validation of the pulmonary score: an asthma severity score for children. Acad Emerg Med. 2002;9:99-104.
24. Chavasse R, Seddon P, Bara A, McKean M. Short acting beta2-agonists for recurrent wheeze in children under two years of age. Cochrane Database of Systematic Reviews 2002, Issue 2. Art. No.: CD002873.
25. Cates CJ, Crilly JA, Rowe BH. Cámaras es-paciadoras versus nebulizadores para el trata-miento del asma aguda con betaagonistas (Revi-sión Cochrane traducida). En: La Biblioteca Cochrane Plus, 2008 Número 4. Oxford: Update Software Ltd. Disponible en: http://www.upda te-software.com. (Traducida de The Cochrane Library, 2008 Issue 3. Chichester, UK: John Wiley & Sons, Ltd.).
26. Benito Fernández J, Trebolazábala Quiran-te N, Landa Garriz M, Mintegui Raso S, González Díaz C. Broncodilatadores inhalados mediante MDI con cámara espaciadora en urgencias pe-diátricas: ¿cuál es la dosis? An Pediatr (Barc). 2006;64:46-51.
27. Everard M, Bara A, Kurian M, N'Diaye T, Ducharme F, Mayowe V. Anticholinergic drugs for wheeze in children under the age of two years. Cochrane Database of Systematic Reviews 2005, Issue 3. Art. No.: CD001279.
28. Vuillermin P, South M, Robertson C. Pa-rent-initiated oral corticosteroid therapy for in-termittent wheezing illnesses in children (Coch-rane Review). En: The Cochrane Library, Issue 3. Chichester, UK: John Wiley & Sons Ltd; 2006.
29. Ducharme FM, Chabot G, Polychronakos C, Glorieux F, Mazer B. Safety profile of frecuent short courses of oral glucocorticoids in acute pediatric asthma: impact on bone metabolism, bo-ne density and adrenal function. Pediatrics. 2003;111:376-83.
30. Jiménez Cortés A, Praena Crespo M, Lora Espinosa A, Grupo de Vías Respiratorias de la AEPap. Normas de calidad para el tratamiento de la crisis de asma en el niño y adolescente. Docu-mentos técnicos del GVR (publicación DT-GVR-1) [consultado el 10/10/2008]. Disponible en www.aepap.org/gvr/protocolos.htm
31. Jiménez Cortés A, Mola Caballero de Rodas P. Tratamiento de la crisis de asma. En: Cano A, Díaz-Vazquez C, Montón JL, editores. Asma en el niño y Adolescente. 2.a Edición. Madrid: Er-gon; 2004. p.115-26.
32. Pérez-Yarza EG, Sardón Prado O, Korta Murua J. Sibilancias recurrentes en menores de tres años: evidencias y oportunidades. An Pediatr (Barc). 2008;69:369-82.
33. Chavasse RJ, Bastian-Lee Y, Richter H, Hilliard T, Seddon P. Persistent wheezing in infants with an atopic tendency responds to inhaled flu-ticasone. Arch Dis Child. 2001;85:143-8.
34. Teper AM, Kofman CD, Szulman GA, Vi-daurreta SM, Maffey AF. Fluticasone improves pulmonary function in children under 2 years old with risk factors for asthma. Am J Respir Crit Ca-re Med. 2005;171:587-90.
35. Guilbert TW, Morgan WJ, Zeiger RS. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med. 2006;354:1985-97.
36. Roorda RJ, Mezei G, Bisgaard H, Maden C. Response of preschool children with asthma symptoms to fluticasone propionate. J Allergy Clin Immunol. 2001;108:540-6.
37. Kaditis AG, Winnie G, Syrogiannopoulos GA. Antiinflammatory pharmacotherapy for wheezing in preschool children. Pediatr Pulmonol. 2007;42:407-20.
38. The Childhood Asthma Management Pro-gram Research Group. Long-term effects of bu-desonide or nedocromil in children with asthma. N Engl J Med. 2000;343:1054-63.
39. Murray CS, Woodcock A, Langley SJ, Morris J, Custovic A. Secondary prevention of asthma by the use of inhaled fluticasone wheezy infants (IFWIN): double-blind, randomised, con-trolled study. Lancet. 2006;368:754-62.
40. García Vera C, Ibáñez Pradas V. El uso de propionato de fluticasona inhalado no parece mo-dificar la historia natural del asma en niños menores de cinco años con sibilancias. Evid Pediatr. 2006;2:77 [consultado el 13/01/2009]. Disponible en www.aepap.org/EvidPediatr/index.htm
41. Bisgaard H, Hermansen MN, Loland L, Halkjaer LB, Bulchvald F. Intermitent inhaled cor-tocosteroids in infants with episodic wheezing. N Engl J Med. 2006;354:1998-2005.
42. Fino E, González de Dios J. En niños menores de tres años con alto riesgo de asma y episo-dios de sibilancias, la administración precoz de corticoides inhalados de forma intermitente no produce beneficios en la evolución del espasmo bronquial de episódico a persistente ni tampoco efectos a corto plazo. Evid Pediatr. 2006;2:42 [consultado el 13/01/2009]. Disponible en www. aepap.org/EvidPediatr/index.htm
43. McKean M, Ducharme F. Inhaled steroids for episodic viral wheeze of childhood. Cochrane Database of Systematic Reviews 2000, Issue 1. Art. No.: CD001107.
44. Schokker S, Kooi EM, de Vries TW, Brand PL, Mulder PG, Duiverman EJ, et al. Inhaled cor-ticosteroids for recurrent respiratory symptoms in preschool children in general practice: rando-mized controlled trial. Pulm Pharmacol Ther. 2008;21:88-97.
45. Knorr B, Franchi LM, Bisgaard H. Montelu-kast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics. 2001;108:e48.
46. Bisgaard H, Zielen S, Garcia-Garcia ML. Montelukast reduces asthma exacerbations in 2-to 5-year-old children with intermittent asthma. Am J Respir Crit Care Med. 2005;171:315-22.
47. Johnston NW, Mandhane PJ, Dai J. Attenuation of the September epidemic of asthma exacerbations in children: a randomized, controlled trial of montelukast added to usual therapy. Pediatrics. 2007;120:e702-712.
48. Robertson CF, Price D, Henry R. Short-course montelukast for intermittent asthma in children: a randomized controlled trial. Am J Res-pir Crit Care Med. 2007:175:323-9.
49. Straub DA, Moeller A, Minocchieri S. The effect of montelukast on lung function and ex-haled nitric oxide in infants with early childhood asthma. Eur Respir J. 2005;25:289-94.
50. Straub DA, Minocchieri S, Moeller A, Ha-macher J, Wildhaber JH. The effect of montelu-kast on exhaled nitric oxide and lung function in asthmatic children 2 to 5 years old. Chest. 2005; 127:509-14.
51. Ng D, Di Salvio F, Hicks G. Agentes anti-leucotrienos comparados con corticosteroides in-halados para el tratamiento del asma recurrente y/o crónica en adultos y niños (Revisión Cochra-ne traducida). En: La Biblioteca Cochrane Plus, 2008 Número 4. Oxford: Update Software Ltd. Disponible en: http://www.update-software. com. (Traducida de The Cochrane Library, 2008 Issue 3. Chichester, UK: John Wiley & Sons, Ltd.).
52. Szefler SJ, Baker JW, Uryniak T, Goldman M, Silkoff PE. Comparative study of budesonide inhalation suspension and montelukast in young children with mild persistent asthma. J Allergy Clin Immunol. 2007;120:1043-50.